Breaking News Instant updates and real-time market news.

HDSN

Hudson Technologies

$7.96

-0.07 (-0.87%)

, ASYS

Amtech Systems

$9.64

0.2 (2.12%)

17:48
08/09/17
08/09
17:48
08/09/17
17:48

On The Fly: After Hours Movers

UP AFTER EARNINGS: Hudson Technologies (HDSN), up 20.5%... Amtech Systems (ASYS), up 14.6%... Quorum Health (QHC), up 7.5%... 22nd Century (XXII), up 6.7%... Live Nation (LYV), up 5.3%... Sangamo (SGMO), up 5.3%... Organovo (ONVO), up 5.3%... 21st Century Fox (FOXA), up 0.7%. ALSO HIGHER: Galapagos NV (GLPG), up 16.2% in New York after it announced "positive" toppline results from its FLORA Phase 2a trial. DOWN AFTER EARNINGS: Babcock & Wilcox (BW), down 29.2%... Quantum (QTM), down 22.3%... CB&I (CBI), down 20.2%... Masonite (DOOR), down 14.9%... Aqua Metals (AQMS), down 6.2%... Bellicum Pharmaceuticals (BLCM), down 2.8%. ALSO LOWER: Kura Oncology (KURA), down 9.9% after it filed to sell 5.3M shares of common stock.

HDSN

Hudson Technologies

$7.96

-0.07 (-0.87%)

ASYS

Amtech Systems

$9.64

0.2 (2.12%)

QHC

Quorum Health

$3.06

-0.08 (-2.55%)

XXII

22nd Century

$2.24

-0.15 (-6.28%)

LYV

Live Nation

$37.50

-0.36 (-0.95%)

SGMO

Sangamo

$8.45

-0.25 (-2.87%)

ONVO

Organovo

$2.08

-0.02 (-0.95%)

FOX

21st Century Fox

$27.51

-0.2 (-0.72%)

FOXA

21st Century Fox

$27.90

-0.13 (-0.46%)

GLPG

Galapagos NV

$73.17

-0.73 (-0.99%)

BW

Babcock & Wilcox

$9.75

-0.07 (-0.71%)

QTM

Quantum

$7.41

-0.18 (-2.37%)

CBI

CB&I

$16.33

-0.08 (-0.49%)

DOOR

Masonite

$72.75

-0.25 (-0.34%)

AQMS

Aqua Metals

$10.87

-0.02 (-0.18%)

BLCM

Bellicum Pharmaceuticals

$8.44

-2.275 (-21.24%)

KURA

Kura Oncology

$9.10

0.1 (1.11%)

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 10

    Aug

  • 10

    Aug

  • 14

    Aug

  • 15

    Aug

  • 15

    Aug

  • 16

    Aug

  • 26

    Sep

  • 11

    Aug

HDSN Hudson Technologies
$7.96

-0.07 (-0.87%)

05/16/17
CHLM
05/16/17
NO CHANGE
Target $10
CHLM
Buy
Hudson Tech a likely beneficiary of refrigerant shortages, says Craig-Hallum
Craig-Hallum analyst Steven Dyer said his checks on certain HFC refrigerants indicate recent sharp price increases and his industry sources expect further hikes through the summer as supply shortages persist. Dyer, who sees the recent refrigerants price surge as likely to positively impact Hudson Technologies' revenue and margins, reiterates his Buy rating and $10 price target on the shares.
03/13/17
RILY
03/13/17
INITIATION
Target $9
RILY
Buy
Hudson Technologies resumed with a Buy at B. Riley
B. Riley analyst Ian Corydon resumed coverage of Hudson Technologies with a Buy rating and $9 price target.
ASYS Amtech Systems
$9.64

0.2 (2.12%)

08/04/17
08/04/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Square (SQ) initiated with a Neutral at Wedbush. 2. Avis Budget (CAR) was initiated with an Overweight at JPMorgan while Hertz (HTZ) was initiated with a Neutral at the firm. 3. IBM (IBM) initiated with a Neutral at Wedbush. 4. Amtech Systems (ASYS) initiated with a Buy at Roth Capital. 5. Franklin Financial Network (FSB) initiated with a Market Perform at Hovde Group. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/04/17
ROTH
08/04/17
INITIATION
Target $12
ROTH
Buy
Amtech Systems initiated with a Buy at Roth Capital
Roth Capital analyst Philip Shen started Amtech Systems with a Buy rating and $12 price target, stating that its record high backlog provides visibility for strong near-term revenue growth through this solar capex cycle.
04/26/17
BNCH
04/26/17
UPGRADE
Target $8
BNCH
Buy
Amtech Systems upgraded to Buy from Hold at Benchmark
Benchmark analyst Mark Miller upgraded Amtech Systems to Buy from Hold after the company announced its solar subsidiary received a follow-on order for the second phase of a multi-phase 1GW project and he also believes other orders related to the project are possible this year. Miller set an $8 price target on Amtech shares.
QHC Quorum Health
$3.06

-0.08 (-2.55%)

05/12/17
05/12/17
NO CHANGE

Quorum Health signs agreement to divest two hospitals in Tennessee
Quorum Health has signed a definitive agreement to sell 45-bed Henderson County Community Hospital in Lexington, Tennessee, and 45-bed McKenzie Regional Hospital in McKenzie, Tennessee, and their associated assets, to SSH Tennessee. The divestiture is expected to close by August 1, subject to customary regulatory approvals and closing conditions.
08/11/16
08/11/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wendy's (WEN) downgraded to Buy from Conviction Buy at Goldman with analyst Karen Holthouse citing execution risk and the potential for additional fiscal 2016 same-store sales guidance reductions. 2. Bristol-Myers (BMY) downgraded to Hold from Buy at Berenberg. 3. Public Storage (PSA) downgraded to Neutral from Buy at BofA/Merrill with analyst Jeffery Spector citing valuation and increasing concessions in weaker markets. 4. Lam Research (LRCX) downgraded to Neutral from Buy at Nomura with analyst Romit Shah citing the extended timeline for its merger with KLA-Tencor (KLAC) after the Department of Justice requested more information. 5. Quorum Health (QHC) downgraded to Sell from Neutral at UBS with analyst A.J. Rice saying the company's earnings power is "much less than thought" after its second quarter results missed expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/04/17
DBAB
04/04/17
INITIATION
DBAB
Hold
Quorum Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Chris Rigg initiated Quorom Health with a Hold rating and a $5 price target.
06/06/17
MSCO
06/06/17
INITIATION
Target $3
MSCO
Underweight
Quorum Health initiated with an Underweight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated Quorum Health with an Underweight and a $3 price target saying long-term growth remains a questions and unemployment is higher than average in the company's markets.
XXII 22nd Century
$2.24

-0.15 (-6.28%)

LYV Live Nation
$37.50

-0.36 (-0.95%)

06/19/17
06/19/17
DOWNGRADE

Neutral
Live Nation downgraded to Neutral on valuation at Northcoast
As previously reported, Northcoast downgraded Live Nation to Neutral from Buy. Analyst John Healy said fundamentals remain intact but changed his rating due to recent share outperformance.
06/27/17
JEFF
06/27/17
NO CHANGE
Target $40
JEFF
Buy
Live Nation price target raised to $40 from $36 at Jefferies
Jefferies analyst John Janedis raised his price target for Live Nation to $40 on expectations for a strong summer concert season. The stock should continue outperforming as the market gives the company more credit for "strong secular tailwinds" across the portfolio, the analyst tells investors in a research note. He keeps a Buy rating on Live Nation.
07/21/17
WBLR
07/21/17
INITIATION
WBLR
Outperform
Live Nation initiated with an Outperform at William Blair
William Blair analyst Ryan Sundby started Live Nation with an Outperform rating.
06/19/17
NRCS
06/19/17
DOWNGRADE
NRCS
Neutral
Live Nation downgraded to Neutral from Buy at Northcoast
SGMO Sangamo
$8.45

-0.25 (-2.87%)

09/06/16
WELS
09/06/16
NO CHANGE
WELS
Outperform
Wells calls Sangamo an 'attractive new investment opportunity'
After the FDA granted orphan drug designation to its Factor IX gene-editing product candidate, SB-FIX, as a treatment for hemophilia B, Wells Fargo analyst Jim Birchenough calls Sangamo BioSciences an "attractive new investment opportunity." Along with validating a commercial opportunity in hemophilia, SB-FIX could provide "even more valuable validation of targeting and coopting the albumin gene locus for gene insertion that may apply to a wide variety of genetic diseases," Birchenough tells investors in a research note. He keeps an Outperform rating on the shares.
10/19/16
PIPR
10/19/16
DOWNGRADE
PIPR
Neutral
Sangamo downgraded to Neutral from Overweight at Piper Jaffray
11/01/16
WEDB
11/01/16
DOWNGRADE
WEDB
Neutral
Sangamo downgraded to Neutral from Outperform at Wedbush
ONVO Organovo
$2.08

-0.02 (-0.95%)

01/24/17
RAJA
01/24/17
INITIATION
Target $5
RAJA
Outperform
Organovo initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initaited Organovo with an Outperform and a $5 price target. The analyst said Organovo is at the early stages of exploring the potential of 3D printed tissue in a variety of therapeutic approaches, including the development of an organ patch for patients with liver injury and has secured 10 of the 25 big pharma as corporate partners in evaluating a variety of drug products including Roche, Merck, Bristol-Myers, and Astellas.
11/28/16
EVER
11/28/16
INITIATION
Target $4.5
EVER
Buy
Organovo initiated with a Buy at Evercore ISI
Target $4.50.
12/15/16
BTIG
12/15/16
INITIATION
BTIG
Buy
Organovo initiated with a Buy at BTIG
BTIG analyst Dr. Sean Lavin started coverage of Organovo with a $5 price target and a Buy rating.
FOX 21st Century Fox
$27.51

-0.2 (-0.72%)

08/08/17
BNCH
08/08/17
NO CHANGE
BNCH
Buy
Fox-ION 'rumors' most likely a negotiating tactic, says Benchmark
Benchmark analyst Daniel Kurnos highlighted a "slew" of "inconsistencies" that make him skeptical of last week's "unsubstantiated rumor published by Bloomberg" regarding Fox (FOXA) potentially forming a JV with ION and pulling all of its affiliate agreements from Sinclair (SBGI), concluding in a note to investors that this was "just another negotiating tactic by the network." Fox's "cozy" agreements with Tribune (TRCO) may get disrupted by Sinclair's acquisition, added Kurnos, who has a Buy rating on Sinclair shares.
04/26/17
FBCO
04/26/17
NO CHANGE
Target $37
FBCO
Outperform
Hulu stake could be for sale this year, says Credit Suisse
Credit Suisse analyst Omar Sheikh notes that Comcast (CMCSA; CMCSK) will be free to sell its 30% stake in Hulu from the end of 2017. The analyst believes there is a $100B domestic revenue opportunity for targeted TV advertising long-term, which vertically integrated networks/distributors will be in a strong position to exploit. Therefore, Sheikh argues that it would make sense for 21st Century Fox (FOX; FOXA) to acquire Comcast's stake in Hulu, if it becomes available, subject to valuation and appropriate programming supply agreements. He reiterates an Outperform rating and $37 price target on 21st Century Fox's shares.
07/25/17
OTRG
07/25/17
DOWNGRADE
OTRG
Mixed
21st Century Fox downgraded to Mixed from Positive at OTR Global
OTR Global downgraded 21st Century Fox to Mixed from Positive
08/01/17
FBCO
08/01/17
NO CHANGE
Target $37
FBCO
Outperform
21st Century Fox, Sky deal to take longer to clear, says Credit Suisse
Credit Suisse analyst Omar Sheikh continues to believe the Sky (SKYAY) transaction will eventually receive full regulatory approval, but highlights there is an elevated risk to the deal if it is referred to the CMA, and at best an extended period before it gets cleared. Meanwhile, he believes the 2018 21st Century Fox (FOXA) organic equity story looks compelling, and reiterates an Outperform rating and $37 price target on the shares.
FOXA 21st Century Fox
$27.90

-0.13 (-0.46%)

07/14/17
WELS
07/14/17
NO CHANGE
WELS
Nexstar Fox deal positive, says Wells Fargo
Wells Fargo says the market is failing to fully appreciate Nexstar's (NXST) deal with 21st Century Fox (FOXA). The analyst says that the OTT master agreement within the deal was positive and removes an overhang on Nexstar. Wells says that the company's management "is doing everything right," and it recommends buying the stock now.
GLPG Galapagos NV
$73.17

-0.73 (-0.99%)

06/22/17
NOMU
06/22/17
NO CHANGE
Target $108
NOMU
Buy
Galapagos NV price target lowered to $108 from $121 at Nomura Instinet
Nomura Instinet analyst Christopher Marai noted that Galapagos revealed during an R&D day that it has pushed back the initiation of its cystic fibrosis triple-combo study to year end from mid-2017, which he believes will delay commercialization of the triple combo to 2022 from his prior 2021 forecast. Given the anticipated delay, he lowered his price target on Galapagos to $108 from $121, though he keeps a Buy rating as he feels CF program readouts may drive near-term upside.
04/24/17
JANY
04/24/17
DOWNGRADE
JANY
Sell
Galapagos NV downgraded to Sell from Buy at Janney Capital
04/24/17
04/24/17
DOWNGRADE
Target $73

Sell
Janney says Galapagos NV 'priced to perfection,' cuts two notches to Sell
As previously reported, Janney Capital analyst Debjit Chattopadhyay downgraded Galapagos NV (GLPG) to Sell from Neutral, stating that while the baricitinib setback suffered by competitors Incyte (INCY) and Eli Lilly (LLY) was "obviously great news," filgotinib is still more than 2 years from commercialization and over seven years away from peak sales. The majority of the positives are already reflected in the stock, even "generously" assuming peak sales for filgotinib above $3B, said Chattopadhyay, who has a $73 fair value estimate on Galapagos shares, which closed Friday at $85.84.
06/22/17
NOMU
06/22/17
NO CHANGE
Target $108
NOMU
Buy
Galapagos NV price target lowered to $108 from $121 at Nomura Instinet
Nomura Instinet analyst Christopher Marai lowered Glapagos' price target to $108 from $121 given the delay in the triple-combo study of its cystic fibrosis program. The analyst is now forecasting commercialization of the triple combo in 2022, versus 2021 previously, saying he continues to view the figotinib program is largely de-risked and maintains a Buy rating.
BW Babcock & Wilcox
$9.75

-0.07 (-0.71%)

03/06/17
JRCO
03/06/17
DOWNGRADE
JRCO
Accumulate
Babcock & Wilcox downgraded to Accumulate from Buy at Johnson Rice
03/03/17
UBSW
03/03/17
NO CHANGE
Target $14
UBSW
Buy
Babcock & Wilcox price target lowered to $14 from $20 at UBS
UBS analyst Steven Fisher lowered his price target on Babcock & Wilcox to $14 from $20 following Q4 results. The analyst called the quarter challenging as the company cited execution issues on a renewable plant in Europe. Fisher reduced his price target to reflect more debt on the balance sheet and a lower multiple. Fisher maintained his Buy rating on Babcock & Wilcox shares.
03/02/17
FBCO
03/02/17
NO CHANGE
Target $10
FBCO
Underperform
Babcock & Wilcox price target lowered to $10 from $16 at Credit Suisse
Credit Suisse analyst Jamie Cook lowered his price target for Babcock & Wilcox to $10 from $16 after the company's Q4 estimates miss related to cost overruns on seven projects within the Renewable segment. The analyst reiterates an Underperform rating on the shares.
03/01/17
KEYB
03/01/17
DOWNGRADE
KEYB
Sector Weight
Babcock & Wilcox downgraded on project difficulties, cash drain at KeyBanc
As noted earlier, KeyBanc downgraded Babcock & Wilcox to Sector Weight from Overweight. Analyst Tahira Afzal downgraded the stock due in part to problems with a project on which the company took a 60c charge. The analyst also cited cash reductions caused by operation issues in the company's renewable unit.
QTM Quantum
$7.41

-0.18 (-2.37%)

10/06/16
LSCM
10/06/16
NO CHANGE
Target $1.5
LSCM
Buy
Quantum price target raised to $1.50 from $1.00 at Lake Street
Lake Street analyst Eric Martinuzzi raised his price target on Quantum to $1.50 from $1.00, citing the company's preannouncement of higher than expected Q2 revenue, which he said continues its recent "encouraging revenue trend reversal." The firm keeps a Buy rating on Quantum shares.
CBI CB&I
$16.33

-0.08 (-0.49%)

07/03/17
BOFA
07/03/17
NO CHANGE
Target $17
BOFA
Underperform
BofA/Merrill says too early to own CB&I
BofA/Merrill analyst Anna Kaminskaya says that while last week's favorable ruling from the Delaware Supreme Court on the outstanding Westinghouse litigation removes the worst case for CB&I, it remains too early to own the shares. Potential cost overruns on the fixed-price projects create downside risks in the second half of 2017, Kaminskaya told investors Friday in a research note. She kept an Underperform rating on CB&I with a $17 price target.
08/07/17
BOFA
08/07/17
NO CHANGE
Target $14
BOFA
Underperform
CB&I price target lowered to $14 from $17 at BofA/Merrill
BofA/Merrill analyst Anna Kaminskaya cut CB&I's (CBI) price target to $14 from $17 saying he sees additional risk from Cameron LNG project charges in Q2. Last week, Sempra (SRE) announced a delay in the Cameron LNG project where CBI is one of the lead contractors. The analyst now assumes a $150M charge on the project and reduced her Q2 earnings estimate to a loss of 18c. Kaminskaya rates CB&I shares an Underperform.
07/24/17
FBCO
07/24/17
DOWNGRADE
Target $21
FBCO
Neutral
CB&I downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Jamie Cook downgraded CB&I to Neutral and maintained a $21 price target given the last two catalysts of the Westinghouse litigation and the closing of the Capital Services sale are behind it, and there are likely challenging quarters ahead. The analyst believes downside may be limited given share underperformance, but believes there is too much negative news flow ahead as fundamentals remain challenged and new awards are likely to disappoint.
07/03/17
FBCO
07/03/17
NO CHANGE
Target $21
FBCO
Outperform
CB&I Capital Services sale provides financial flexibility, says Credit Suisse
Credit Suisse analyst Jamie Cook notes that CB&I announced that it has completed the sale of its Capital Services business to private equity sponsor Veritas for $700M. The analyst views the news as a positive, as the slight haircut was largely expected and timely closing of the deal removes concern that the company would not be able to meet its financial covenants when the total leverage requirement steps down in Q3. Moreover, Cook believes the deal and debt paydown provides more financial flexibility given concerns around inter-period revolver draws/working capital builds in light of problem projects. He reiterates an Outperform rating and $21 price target on the shares.
DOOR Masonite
$72.75

-0.25 (-0.34%)

04/11/17
NOMU
04/11/17
INITIATION
Target $90
NOMU
Buy
Masonite initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Michael Wood started Masonite with a Buy rating and $90 price target.
05/10/17
BARD
05/10/17
NO CHANGE
Target $90
BARD
Outperform
Masonite growth story remains intact, says Baird
Baird analyst Timothy Wojs noted Masonite shares traded lower following its Q1 results as manufacturing inefficiencies in North America overshadowed relatively solid demand and good price/mix improvement. Wojs said despite the misstep, Masonite's growth story remains intact and he reiterated his Outperform rating and $90 price target on Masonite shares.
06/16/17
WEDB
06/16/17
INITIATION
WEDB
Outperform
Masonite coverage assumed with an Outperform at Wedbush
Wedbush analyst Jay McCanless assumed coverage of Masonite with an $85 price target and an Outperform rating. The analyst thinks that the company's strategy of focusing on the door market is correct, and he believes that it can meet the midpoints of its EBITDA and EPS guidance ranges.
05/10/17
RBCM
05/10/17
NO CHANGE
RBCM
Masonite should be bought on weakness, says RBC Capital
RBC Capital analyst Robert Wetenhall recommends buying Masonite on weakness after it reported weaker than expected results. The analyst says that the miss was probably caused by "manufacturing inefficiencies" and "inventory adjustments" by large retailers. He expects these issues to "be resolved," and he keeps a $92 price target and Outperform rating on the shares.
AQMS Aqua Metals
$10.87

-0.02 (-0.18%)

06/01/17
OPCO
06/01/17
NO CHANGE
Target $34
OPCO
Outperform
Oppenheimer constructive on Aqua Metals after facility visit
Oppenheimer analyst Colin Rusch says his visit to Aqua Metals' Reno facility suggests the company is tracking well the cost numbers management has guided to, which he views as the biggest issue for the shares. The analyst sees a "significant amount of additional margin" for higher purity lead and believes mix could drive upside to his expectations. Rusch remains "constructive" on the shares with an Outperform rating and $34 price target.
06/22/17
RODM
06/22/17
INITIATION
Target $25
RODM
Aqua Metals initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Amit Dayal initiated Aqua Metals (AQMS) with a Buy and a $25 saying strategic alliances with Johnson Controls (JCI), Interstate Batteries, and Battery Systems validates the company's technology and provides visibility into revenues.
06/22/17
06/22/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Jabil Circuit (JBL) initiated with an Outperform at Macquarie. 2. Magellan Midstream (MMP) initiated with a Hold at Jefferies. 3. AvalonBay (AVB) initiated with a Buy at Argus. 4. Aqua Metals (AQMS) initiated with a Buy at Rodman & Renshaw. 5. Del Taco (TACO) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/13/17
OPCO
03/13/17
NO CHANGE
Target $34
OPCO
Outperform
Aqua Metals price target raised to $34 from $16 at Oppenheimer
Oppenheimer analyst Colin Rusch raised his price target for Aqua Metals (AQMS) to $34 from $16 after the company's recent filings and in light of its strategic agreement with Johnson Controls (JCI). The analyst continues to believe this agreement is transformative for Aqua Metals as it provides the company with stable, clearly priced demand for five years, and provides a key licensee for its technology and a partner for using the value-added product of its AquaRefining process. He reiterates an Outperform rating on Aqua Metals' shares.
BLCM Bellicum Pharmaceuticals
$8.44

-2.275 (-21.24%)

06/23/17
LTCO
06/23/17
NO CHANGE
Target $31
LTCO
Buy
Bellicum selloff after 'strong' data unwarranted, says Ladenburg
Ladenburg Thalmann analyst Wangzhi Li said the updated data Bellicum presented on BPX-501 further strengthens its impressive profile and he sees a high probability for BPX-501 to meet the primary endpoint for an MAA filing. He believes the selloff in the stock as unwarranted and recommends taking advantage to build positions. Li keeps a Buy rating and $31 price target on Bellicum shares.
06/02/17
LTCO
06/02/17
NO CHANGE
Target $31
LTCO
Buy
Bellicum pullback a buying opportunity, says Ladenburg
Ladenburg Thalmann analyst Wangzhi Li views the recent pullback in shares of Bellicum Pharmaceuticals as a buying opportunity. The selloff is unwarranted and represents a lack of appreciation of the upcoming highlight of BPX-501 data on June 23, Li tells investors in a research note. The analyst does not see a fundamental event that triggered the selloff in the past week. Li keeps a Buy rating on Bellicum with a $31 price target.
03/08/17
WELS
03/08/17
INITIATION
WELS
Outperform
Bellicum Pharmaceuticals initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Bellicum Pharmaceuticals with an Outperform rating and $28-$31 price target range. The analyst believes the company's "switch technology" to turn cell therapeutics "on" and "off" will be at the forefront of a wave of new therapeutics.
12/01/16
RAJA
12/01/16
INITIATION
Target $29
RAJA
Outperform
Bellicum Pharmaceuticals initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated Bellicum Pharmaceuticals with an Outperform and a $29 price target.
KURA Kura Oncology
$9.10

0.1 (1.11%)

10/13/16
LEER
10/13/16
INITIATION
Target $15
LEER
Outperform
Kura Oncology reinstated with an Outperform at Leerink
Leerink analyst Jonathan Chang resumed coverage of Kura Oncology with an Outperform rating and $15 price target, saying he views it as "attractively valued" heading into data rich 2017.
08/08/17
SBSH
08/08/17
NO CHANGE
Target $13
SBSH
Buy
Kura Oncology Phase 2 trial update 'encouraging,' says Citi
Citi analyst Joel Beatty views Kura Oncology's Phase 2 HRAS mutant SCCHN trial update as "encouraging." Though the number of patients is still small, the 60% partial response rate is higher than the 13%-16% rate seen historically with approved agents in the squamous cell carcinomas of the head and neck setting, Beatty tells investors in a research note. He raised his price target for Kura shares to $13 from $12 and keeps a Buy rating on the name.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$312.60

-5.21 (-1.64%)

08:08
11/23/17
11/23
08:08
11/23/17
08:08
Hot Stocks
Tesla CEO highlights 'record time' on Australian ion battery »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

TSLA

Tesla

$312.60

-5.21 (-1.64%)

08:07
11/23/17
11/23
08:07
11/23/17
08:07
Hot Stocks
Tesla completes construction on largest lithium ion battery in Australia »

The South Australian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

GSK

GlaxoSmithKline

$35.06

0.25 (0.72%)

, INVA

Innoviva

$13.42

0.01 (0.07%)

07:56
11/23/17
11/23
07:56
11/23/17
07:56
Hot Stocks
GSK, Innoviva submit data to FDA for expanded Trelegy Ellipta label »

GlaxoSmithKline (GSK) and…

GSK

GlaxoSmithKline

$35.06

0.25 (0.72%)

INVA

Innoviva

$13.42

0.01 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVM

Silvercorp Metals

$2.51

-0.07 (-2.71%)

07:52
11/23/17
11/23
07:52
11/23/17
07:52
Hot Stocks
Silvercorp Metals to buy back up to 5% of shares »

Silvercorp Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEL

Cellcom Israel

$10.00

-0.1 (-0.99%)

07:49
11/23/17
11/23
07:49
11/23/17
07:49
Hot Stocks
Cellcom Israel now second layer company according to Concentration Law »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GASS

StealthGas

$4.07

0.36 (9.70%)

07:06
11/23/17
11/23
07:06
11/23/17
07:06
Recommendations
StealthGas analyst commentary  »

StealthGas trades at only…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$41.01

4.31 (11.74%)

07:02
11/23/17
11/23
07:02
11/23/17
07:02
Recommendations
Copart analyst commentary  »

Copart price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

DE

Deere

$145.25

6.02 (4.32%)

06:56
11/23/17
11/23
06:56
11/23/17
06:56
Upgrade
Deere rating change  »

Deere upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

DE

Deere

$145.25

6.02 (4.32%)

06:55
11/23/17
11/23
06:55
11/23/17
06:55
Recommendations
Deere analyst commentary  »

Deere price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

06:40
11/23/17
11/23
06:40
11/23/17
06:40
General news
FX Update: The dollar has remained on a weakening track »

FX Update: The dollar has…

SECO

Seeco Holding

$8.34

0.14 (1.71%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
Seeco Holding management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
Deutsche Bank to hold a conference »

Thailand SET Corporate…

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
RBC Capital to hold field trip »

European Utilities Field…

BASFY

BASF

$27.39

-0.13 (-0.47%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
BASF management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

  • 24

    Nov

RBS

RBS

$7.30

-0.04 (-0.54%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
RBS management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

  • 24

    Nov

04:25
11/23/17
11/23
04:25
11/23/17
04:25
General news
FX Action: USD-CAD punched out a 10-day low »

FX Action: USD-CAD…

02:35
11/23/17
11/23
02:35
11/23/17
02:35
General news
FX Update: The dollar has remained on a downward path »

FX Update: The dollar…

L

Loews

$49.36

-0.02 (-0.04%)

, GE

General Electric

$18.15

0.32 (1.79%)

18:41
11/22/17
11/22
18:41
11/22/17
18:41
Hot Stocks
Loews CEO James Tisch buys 3M shares of General Electric »

In a regulatory filing,…

L

Loews

$49.36

-0.02 (-0.04%)

GE

General Electric

$18.15

0.32 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRFS

BRF S.A.

$12.77

-0.16 (-1.24%)

18:06
11/22/17
11/22
18:06
11/22/17
18:06
Hot Stocks
BRF S.A. names Jose Aurelio Drummond Jr. as CEO »

BRF S.A. hereby informs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$35.42

0.2 (0.57%)

18:02
11/22/17
11/22
18:02
11/22/17
18:02
Hot Stocks
Suncor closes sale of equity interest in East Tan Farm, redeems $750M in debt »

Suncor successfully…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SAP

SAP

$113.85

-1.44 (-1.25%)

17:53
11/22/17
11/22
17:53
11/22/17
17:53
Periodicals
SAP launches investigation of sales practices in Gulf region, Reuters reports »

SAP has launched a formal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$180.87

-0.99 (-0.54%)

17:47
11/22/17
11/22
17:47
11/22/17
17:47
Periodicals
Facebook tool to show users which content was Russian propaganda, says Bloomberg »

Facebook will add a tool…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$51.01

0.79 (1.57%)

17:24
11/22/17
11/22
17:24
11/22/17
17:24
Periodicals
CSX to charge more fees on customers that disregard shipping rules, Reuters says »

Starting on January 1st,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AYTU

Aytu BioScience

$3.03

0.4301 (16.54%)

17:10
11/22/17
11/22
17:10
11/22/17
17:10
Syndicate
Breaking Syndicate news story on Aytu BioScience »

Aytu BioScience files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPIX

ESSA Pharma

$0.27

0.0059 (2.27%)

17:09
11/22/17
11/22
17:09
11/22/17
17:09
Hot Stocks
ESSA Pharma to begin trading on TSX Venture Exchange »

ESSA Pharma is listing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.